BrainSpace Medical

BrainSpace operates in medical devices and neurotechnology, focusing on brain and spine protection and hospital-based brain-fluid management. Its FDA 510(k)-cleared Intellidrop system gives it a concrete regulatory and product milestone in a specialized clinical area, rather than positioning it solely around an in-development concept. The company’s stated team differentiators include experience across medical-device design, process engineering, commercial manufacturing, embedded software, and quality management; team members have contributed to four FDA-approved devices and are named on more than 100 patents. Clinical and commercial advisors are described as bringing hospital leadership, neuroscience, and device-commercialization expertise. These capabilities may matter in a market where clinical integration, safety, manufacturing readiness, and regulatory execution shape adoption. BrainSpace’s record indicates a small, privately held operation, with an employee-size band of 11–50 and two current positions listed. Its competitive position will depend in part on commercial uptake of Intellidrop and evidence of performance in hospital settings.

BrainSpace’s financing and product milestones suggest a progression from early development toward commercialization. The company was founded in 2021 and announced a $3 million seed round in July 2022, followed by $2.17875 million in debt financing in July 2023. A May 2024 non-equity assistance round added MedTech Innovator as a lead investor, and further debt financing totaled $325,000 in March 2025 and $1.025 million in February 2026. The 2022 seed and disclosed debt rounds together account for the reported $6.52875 million total; the pre-seed and non-equity assistance rounds have no disclosed amounts. The key inflection point is the January 2, 2026 FDA 510(k) clearance of Intellidrop, which the company described as enabling commercial launch in U.S. hospitals. This shifts the company’s trajectory from product development toward commercialization, although public information does not establish sales, deployments, or revenue. The stated employee range is 11–50, while two current leadership positions are listed, so the available figures do not establish a hiring trend. Growth will depend on converting regulatory clearance into hospital adoption and sustaining execution with a relatively small team.